A groundbreaking study that might help in understanding the progression of a dangerous kind of breast cancer may pave the way for the development of new medicines.

Scientists are hopeful that the creation of new medications will halt the formation of tumors.

The aggressive type of breast cancer 'triple negative' generally impinges on younger women and the foremost treatment for this will be created after British investigators make a "major advance" in its understanding.

It is speculated that every year, out of the 46,000 women who are diagnosed with breast cancer, around 9,000 will suffer from this form. And a number of them are in their 30s.

Presently, the only available treatment recommended for 'triple negative' breast cancer is operation and general chemotherapy. It is reported that the mortality rate for this disease is quite high compared to other types of breast cancer.

Triple negative breast cancer is dubbed after the information that the resulting tumors are not motivated by oestrogen and progesterone hormones, or the HER2 protein, as the majority of them are.

Dr. Matt Smalley, of Breakthrough Breast Cancer's Institute of Cancer Research in London, said, "This knowledge will greatly improve the chance of finding effective new targeted treatments for breast cancer patients in the future".